0001193125-23-014850.txt : 20230125 0001193125-23-014850.hdr.sgml : 20230125 20230125090003 ACCESSION NUMBER: 0001193125-23-014850 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230125 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230125 DATE AS OF CHANGE: 20230125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 23549946 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 8-K 1 d439029d8k.htm 8-K 8-K
false 0001750149 0001750149 2023-01-25 2023-01-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2023

 

 

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39676   26-3407249

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

3350 Riverwood Parkway SE, Suite 1900

Atlanta, Georgia

   30339
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (678) 392-3419

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   IKT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01 Other Events.

On January 25, 2023, Inhibikase Therapeutics, Inc. (the “Company”) issued a press release announcing that the full clinical hold on IkT-148009 in Parkinson’s disease has been lifted by the U.S. Food and Drug Administration. A copy of the Company’s press release regarding the lifting of the clinical hold is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On January 25, 2023, the Company also issued a press release announcing the publication of studies describing the potential of IkT-148009 as a disease-modifying therapy for Parkinson’s disease and related disorders. A copy of the Company’s press release regarding the publication is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Number   

Description

99.1    Press Release dated January 25, 2023 (Clinical Hold).
99.2    Press Release dated January 25, 2023 (Publication).
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 25, 2023   INHIBIKASE THERAPEUTICS, INC.
    By:  

/S/ MILTON H. WERNER

      Milton H. Werner, Ph.D.
      President and Chief Executive Officer

 

-3-

EX-99.1 2 d439029dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson’s Disease

- Phase 2a ‘201’ clinical trial will resume immediately at 50 and 100 mg doses-

-Additional safety and pharmacokinetic information will be measured in healthy subjects at the 200 mg

dose prior to implementation in the 201 trial-

BOSTON and ATLANTA, January 25, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the U.S. Food and Drug Administration (“FDA” or “Agency”) has lifted the full Clinical Hold on IkT-148009 in Parkinson’s disease (PD).

“We are grateful for the expeditious review by the FDA of our response to the Clinical Hold on IkT-148009 in PD,” stated Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics. “We believe that we now have clarity on the FDA’s expectations as we move forward in the 201 clinical trial for IkT-148009. We are now working to re-open clinical trial sites and initiate screening and enrollment of patients for the trial following agreed upon updates to the Protocol and Informed Consent form. We anticipate completing these restart tasks by the end of the first quarter.”

IkT-148009 is a c-Abl tyrosine kinase inhibitor that has been shown to halt disease progression, protect and restore lost neurons and to clear the underlying protein pathology in animal studies that suggests a causal link to the initiation and progression of disease in humans1. In lifting the clinical hold, the Agency based their decision on the Company’s Complete Response and Amendment dated December 21, 2022, as well as further commitments made on January 20, 2023 regarding ophthalmologic monitoring in the protocol of study IkT-148009-201 and various modifications to the Investigator Brochure. The Agency requested that the Company measure the safety and steady-state pharmacokinetic (PK) profile of the 200 mg dose in six (6) healthy subjects prior to administration of the 200 mg dose in Parkinson’s patients. The 201 trial will resume at the 50 mg and 100 mg dose immediately and the safety/PK measurement at 200 mg will be performed simultaneously.

The Agency further requested the measurement of visual acuity and examination of the cornea and lens to complement the analysis of retina, macula and fundus that was already part of the ocular monitoring program in the 201 trial. This monitoring program is consistent with the monitoring program for ocular pathology of other approved protein kinase inhibitors. To date, no ocular pathology has been observed in any trial participant administered IkT-148009.

The Agency further requested removal of safety-related data in the Investigator Brochure for the primary metabolites of IkT-148009 to give the Agency time to review the underlying report in support of this safety data.

With agreement on conditions for restart of the 201 trial and the lifting of the clinical hold on IkT-148009, the Company intends to seek a lifting of the Clinical Hold on its program focused on Multiple System Atrophy (MSA).

 

1 

DOI: 10.1126/scitranslmed.abp9352

 

Inhibikase Therapeutics, Inc.       Page 1 of 2
3350 Riverwood Parkway, Suite 1900    
Atlanta, GA 30339   www.inhibikase.com  

About Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include factors that are delineated in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Company Contact:

Milton H. Werner, Ph.D.

President & CEO

678-392-3419

info@inhibikase.com

Investor Relations:

Alex Lobo

SternIR, Inc.

alex.lobo@sternir.com

# # #

 

Inhibikase Therapeutics, Inc.       Page 2 of 2
3350 Riverwood Parkway, Suite 1900    
Atlanta, GA 30339   www.inhibikase.com  
EX-99.2 3 d439029dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson’s Disease and Related Disorders

- Animal model studies highlight potential of the c-Abl inhibitor IkT-148009 to modify the course of

Parkinson’s Disease and Suppress Protein Pathology -

BOSTON and ATLANTA, January 25, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the publication of studies describing the potential of IkT-148009 as a disease-modifying therapy for Parkinson’s disease and related disorders.    The publication entitled “The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease” was published online in the journal Science Translational Medicine on January 18, 2023 (DOI: 10.1126/scitranslmed.abp9352)

“Understanding the mechanisms underlying the initiation and progression of Parkinson’s disease (PD) inside and outside of the brain has remained a significant challenge to the development of disease-modifying therapeutics in PD,” stated Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics. “In published work by our collaborators1, genetic deletion of c-Abl blocked neurodegeneration in animals that exhibited alpha-synuclein aggregates or ‘plaques’, suggesting the essential role of c-Abl in the disease process. In this publication, we highlighted the neurodegenerative functional screen that led to the identification of IkT-148009. The publication also highlights data from once daily oral administration of IkT-148009 in multiple animal models that mimicked the rate of disease progression found in human PD. Results from these studies demonstrated the ability of IkT-148009 to halt disease progression, drive functional recovery, and protect neurons in the brain from degradation. The exposures to IkT-148009 used in these model studies are consistent with the exposures to IkT-148009 at a 50 mg oral dose in PD patients, one of the doses that is being evaluated in our Phase 2a ‘201’ clinical trial in untreated Parkinson’s patients. Remarkably, therapeutic benefit in these models was accompanied by substantial reduction of alpha-synuclein pathology in the brain, a long-sought goal of Parkinson’s treatment. We believe that these data demonstrate the potential of IkT-14809 as a disease modifying therapy and support the continued clinical development of IkT-148009.”

Key highlights included:

 

  •  

Demonstration of enzyme selectivity within the c-Abl family for IkT-148009

 

  •  

Implementation of a functional neurodegenerative screen enabling identification of IkT-148009 as a potential therapeutic to suppress c-Abl activation in the brain

 

  •  

Demonstration that IkT-148009 is therapeutically active as a disease-modifying treatment in animal models of PD at the same doses being evaluated in the 201 trial

 

  •  

Provides clarity on how misfolded protein aggregates initiate and progress neurodegenerative diseases

 

  •  

Correlates removal of protein aggregates following c-Abl inhibition by IkT-148009 with functional recovery in multiple models of human disease, a long sought goal of treatment

 

1 

(Brahmachari et al. Brain. 2019. PMID: 31237944)

 

Inhibikase Therapeutics, Inc.       Page 1 of 2
3350 Riverwood Parkway, Suite 1900    
Atlanta, GA 30339   www.inhibikase.com  

About Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements, including that results in animal studies may not be replicated in humans. Important factors that could cause actual results to differ materially from those in the forward-looking statements include factors that are delineated in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Company Contact:

Milton H. Werner, Ph.D.

President & CEO

678-392-3419

info@inhibikase.com

Investor Relations:

Alex Lobo

SternIR, Inc.

alex.lobo@sternir.com

# # #

 

Inhibikase Therapeutics, Inc.       Page 2 of 2
3350 Riverwood Parkway, Suite 1900    
Atlanta, GA 30339   www.inhibikase.com  
EX-101.SCH 4 ikt-20230125.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 ikt-20230125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 6 ikt-20230125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g439029g0125090001021.jpg GRAPHIC begin 644 g439029g0125090001021.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Jan. 25, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001750149
Document Type 8-K
Document Period End Date Jan. 25, 2023
Entity Registrant Name INHIBIKASE THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39676
Entity Tax Identification Number 26-3407249
Entity Address, Address Line One 3350 Riverwood Parkway SE
Entity Address, Address Line Two Suite 1900
Entity Address, City or Town Atlanta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30339
City Area Code (678)
Local Phone Number 392-3419
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol IKT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 9 d439029d8k_htm.xml IDEA: XBRL DOCUMENT 0001750149 2023-01-25 2023-01-25 false 0001750149 8-K 2023-01-25 INHIBIKASE THERAPEUTICS, INC. DE 001-39676 26-3407249 3350 Riverwood Parkway SE Suite 1900 Atlanta GA 30339 (678) 392-3419 false false false false Common Stock, $0.001 par value IKT NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d439029d8k.htm d439029dex991.htm d439029dex992.htm ikt-20230125.xsd ikt-20230125_lab.xml ikt-20230125_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d439029d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d439029d8k.htm" ] }, "labelLink": { "local": [ "ikt-20230125_lab.xml" ] }, "presentationLink": { "local": [ "ikt-20230125_pre.xml" ] }, "schema": { "local": [ "ikt-20230125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ikt", "nsuri": "http://www.inhibikase.com/20230125", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d439029d8k.htm", "contextRef": "duration_2023-01-25_to_2023-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d439029d8k.htm", "contextRef": "duration_2023-01-25_to_2023-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inhibikase.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-23-014850-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-014850-xbrl.zip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end